Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

6.780 -0.260 (-3.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 158,667
Open 7.050
Bid (Size) 6.530 (100)
Ask (Size) 7.900 (900)
Prev. Close 7.040
Today's Range 6.780 - 7.175
52wk Range 6.110 - 11.78
Shares Outstanding 37,759,825
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-0.4%
-0.4%
1 Month
-21.6%
-21.6%
3 Month
-6.6%
-6.6%
6 Month
-5.3%
-5.3%
1 Year
-25.4%
-25.4%

More News

Read More
News headline image
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead ↗
Via Stocktwits
News headline image
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Inc (NASDAQ:GYRE) Reports Q3 2025 Earnings Beat Amid Revenue Miss and Lowered Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 7, 2025 ↗
Via Benzinga
News headline image
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
Via Benzinga
BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
Via Investor Brand Network
News headline image
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗
Via Benzinga
News headline image
This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
Via Benzinga
News headline image
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Gyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gyre Therapeutics, Inc. - Common Stock trade on?
Gyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Gyre Therapeutics, Inc. - Common Stock is GYRE on the Nasdaq Stock Market
What is the current price of Gyre Therapeutics, Inc. - Common Stock?
The current price of Gyre Therapeutics, Inc. - Common Stock is 6.780
When was Gyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Gyre Therapeutics, Inc. - Common Stock was at 03/27/26 04:00 PM ET
What is the market capitalization of Gyre Therapeutics, Inc. - Common Stock?
The market capitalization of Gyre Therapeutics, Inc. - Common Stock is 256.01M
How many shares of Gyre Therapeutics, Inc. - Common Stock are outstanding?
Gyre Therapeutics, Inc. - Common Stock has 256M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.